摘要
目的:分析和评价雷珠单抗联合激光治疗视网膜静脉阻塞合并黄斑水肿(retinal vein occlusion complicated with macular edema,RVO-ME)的疗效及安全性。方法:选取2019年1月至2022年1月由中国人民解放军联勤保障部队第901医院眼科诊治的80例(80眼)RVO-ME患者,将其分为研究组与对照组,每组40例(40眼)。对照组患者给予视网膜激光光凝术治疗,研究组患者给予视网膜激光光凝术联合玻璃体注射雷珠单抗治疗。2组患者术后均随访6个月。对2组患者的症状指标和治疗前、治疗6个月末的最佳矫正视力(best corrected visual acuity,BCVA)、黄斑中心厚度(central macular thickness,CMT)、黄斑区视网膜平均厚度(cube average thickness,CAT)进行对比。对于注射雷珠单抗后研究组患者的药物不良反应进行观察,对2组患者的术后并发症进行随访。结果:研究组患者的眼底出血吸收时间、渗出吸收时间、黄斑水肿改善时间等症状指标均低于对照组(均P<0.05)。治疗6个月末,2组患者的BCVA均较治疗前增高,CMT、CAT均较治疗前降低(均P<0.05);研究组患者的BCVA高于对照组,CMT、CAT均低于对照组(均P<0.05)。研究组患者注射雷珠单抗后的不良反应均为轻度眼部不良反应,未经治疗却都能自行缓解。2组患者术后并发症的发生率的差异无统计学意义(P>0.05)。结论:与单纯应用视网膜光凝术治疗比较,对于RVO-ME患者采用视网膜光凝术联合玻璃体注射雷珠单抗进行治疗,对于促进症状缓解、改善术后近期视功能具有积极的意义,且不会提升术后并发症的发生率,安全性较好。
Objective:To analyze and evaluate the efficacy and safety of ranibizumab combined with laser treatment for retinal vein occlusion complicated with macular edema(RVO-ME).Methods:A total of 80 patients(80 eyes)with RVO-ME from Department of Ophthalmology of No.901 Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from January 2019 to January 2022 were selected.The patients were divided into a study group and a control group by random number table method,each group with 40 patients(40 eyes).The patients in the control group were treated with retinal laser photocoagulation,and the patients in the study group were treated with retinal laser photocoagulation combined with vitreous injection of ranibizumab.The patients in both groups were followed up for 6 months.The symptom indexes and the best corrected visual acuity(BCVA),the central macular thickness(CMT),the cube average thickness(CAT)between the 2 groups were compared.The drug-related adverse reactions of patients in the study group after injection of ranibizumab were observed,and the postoperative complications in the 2 groups were followed up and observed.Results:The absorption time of fundus hemorrhage,the absorption time of exudation and the improvement time of macular edema in the study group were lower than those in the control group(all P<0.05).At the end of 6 months after treatment,BCVA in the 2 groups was higher than those before treatment,while CMT,CAT were lower than those before treatment(all P<0.05).BCVA in the study group was higher than that in the control group,CMT,CAT in the study group were lower than those in the control group(all P<0.05).The adverse reactions in the study group after injection of ranibizumab were all mild ocular adverse reactions,which were self alleviated without treatment.There was no significant difference in the incidence of postoperative complications between the 2 groups(P>0.05).Conclusion:Compared with the application of retinal photocoagulation alone,the application of retinal photocoagulation combined with vitreous injection of ranibizumab for RVO-ME patients has positive significance in promoting symptom relief,improving the recent visual function after surgery,will not increase the incidence of postoperative complications and has high safety.
作者
丁连娥
胡风云
陈芬芬
曹晓莉
郑纯
DING Lian’e;HU Fengyun;CHEN Fenfen;CAO Xiaoli;ZHENG Chun(Department of Ophthalmology,No.901 Hospital of Joint Service Support Force of People’s Liberation Army,Hefei 230031,China)
出处
《临床与病理杂志》
CAS
2023年第6期1175-1182,共8页
Journal of Clinical and Pathological Research
